Treatment of resistance to zanubrutinib

Zanubrutinib (Zanubrutinib) is a new oral small molecule targeted therapeutic agent that is a Bruton's tyrosine kinase (BTK) inhibitor. BTK plays a key role in leukocytes and is involved in regulating the growth and maturation of B cells, so it is widely used in the treatment of B cell-related malignancies. However, over time, some patients may develop resistance to zanubrutinib. Resistance may be caused by BTK mutations, enhanced signaling pathway activity, or other changes. According to different resistance mechanisms, corresponding treatment strategies can be selected.

If a patient develops resistance to zanubrutinib, other BTK inhibitors, such as ibrutinib, may be considered. These alternative treatments may have different mechanisms of resistance and may be more effective against resistance. Another strategy is to combine zanubrutinib with other targeted therapeutics or chemotherapeutics, which can enhance therapeutic efficacy and combat resistance by targeting different signaling pathways or employing multiple mechanisms. The latest options for resistance management may be evaluated in clinical trials. Patients may consider participating in relevant clinical trials to obtain the latest treatment options for zanubrutinib resistance. Since everyone's constitution is different, their resistance to drugs is also different. If drug resistance occurs after using the drug, please inform your doctor in time and do not adjust the drug dosage yourself.

The original drug of zanubrutinib has been launched in China and has been included in the medical insurance. The price of each box of 80mg*64 tablets may be around RMB 6,000. The original drug of zanubrutinib marketed overseas is more expensive, and there are currently no generic drugs of zanubrutinib on the market.